A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

ASC30 oral tablet demonstrated superior PK properties (including a longer t1/2 and higher AUC) to other small molecule oral GLP-1 receptor (GLP-1R) agonists in development, suggesting ASC30 oral ...

The toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

GLP-1 agonist drugs like Ozempic and Wegovy have surged in popularity during the last couple of years for their ability to help patients shed weight quickly and potentially reduce inflammation. While ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome ... and improvement in some cholesterol parameters, with a very small increase in heart rate.

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 ...

Glucagon-like peptide-1 receptor agonist medications for weight loss are significantly transforming the field of facial plastic surgery.

“I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards important clinical readouts later this year,” said Mr. Azelby. “I look forward to working with Terns’ ...